Total Payments
$980,569
2024 Payments
$54,050
Companies
19
Transactions
1,076
Medicare Patients
936
Medicare Billing
$256,355
Payment Breakdown by Category
Other$691,149 (70.5%)
Consulting$136,920 (14.0%)
Travel$129,817 (13.2%)
Food & Beverage$22,683 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $677,034 | 261 | 69.0% |
| Consulting Fee | $136,920 | 60 | 14.0% |
| Travel and Lodging | $129,817 | 488 | 13.2% |
| Food and Beverage | $22,683 | 264 | 2.3% |
| Honoraria | $7,040 | 1 | 0.7% |
| Grant | $5,075 | 1 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,000 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $424,256 | 471 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $292,088 | 250 | $0 (2024) |
| Relypsa, Inc. | $88,740 | 159 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $56,617 | 92 | $0 (2018) |
| Mallinckrodt Hospital Products Inc. | $26,969 | 16 | $0 (2021) |
| Eli Lilly and Company | $16,378 | 15 | $0 (2022) |
| Cumberland Pharmaceuticals, Inc. | $14,220 | 9 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,493 | 16 | $0 (2022) |
| Lilly USA, LLC | $10,335 | 11 | $0 (2022) |
| Horizon Pharma plc | $8,132 | 8 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,050 | 40 | AstraZeneca Pharmaceuticals LP ($27,539) |
| 2023 | $138,455 | 121 | Bayer Healthcare Pharmaceuticals Inc. ($96,617) |
| 2022 | $174,948 | 179 | Bayer HealthCare Pharmaceuticals Inc. ($91,393) |
| 2021 | $214,909 | 225 | AstraZeneca Pharmaceuticals LP ($107,247) |
| 2020 | $84,646 | 67 | AstraZeneca Pharmaceuticals LP ($47,076) |
| 2019 | $170,930 | 218 | AstraZeneca Pharmaceuticals LP ($133,674) |
| 2018 | $67,957 | 113 | Relypsa, Inc. ($35,300) |
| 2017 | $74,674 | 113 | Otsuka America Pharmaceutical, Inc. ($43,195) |
All Payment Transactions
1,076 individual payment records from CMS Open Payments — Page 1 of 44
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/18/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $481.89 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $156.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/12/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $106.61 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $84.15 | General |
| Category: Cardio-renal | ||||||
| 07/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,242.00 | General |
| Category: Cardio-renal | ||||||
| 07/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $20.10 | General |
| Category: Cardio-renal | ||||||
| 07/31/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $10.00 | General |
| Category: Cardio-renal | ||||||
| 07/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $116.15 | General |
| Category: Cardio-renal | ||||||
| 07/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $134.10 | General |
| Category: Cardio-renal | ||||||
| 07/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $544.95 | General |
| Category: Cardio-renal | ||||||
| 07/08/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $474.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $124.78 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/25/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Travel and Lodging | In-kind items and services | $107.41 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/16/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/14/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $90.19 | General |
| Category: Hyperkalemia | ||||||
| 05/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $71.65 | General |
| Category: Cardio-renal | ||||||
| 05/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $27.00 | General |
| Category: Cardio-renal | ||||||
| 05/08/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Travel and Lodging | In-kind items and services | $190.85 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/08/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $85.07 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $189.80 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 211 | 388 | $139,788 | $34,458 |
| 2022 | 6 | 181 | 396 | $226,406 | $62,017 |
| 2021 | 7 | 222 | 490 | $278,008 | $76,382 |
| 2020 | 8 | 322 | 647 | $351,627 | $83,498 |
Total Patients
936
Total Services
1,921
Medicare Billing
$256,355
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 59 | 182 | $61,152 | $16,655 | 27.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 63 | 76 | $26,144 | $6,888 | 26.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 32 | 34 | $22,236 | $4,504 | 20.3% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 39 | 76 | $20,976 | $4,270 | 20.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 18 | 20 | $9,280 | $2,141 | 23.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 14 | 126 | $123,984 | $36,577 | 29.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 54 | 146 | $49,056 | $12,157 | 24.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 45 | $29,430 | $6,960 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 41 | 43 | $14,792 | $4,041 | 27.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 18 | $4,176 | $1,244 | 29.8% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 14 | 18 | $4,968 | $1,038 | 20.9% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 21 | 154 | $151,536 | $44,800 | 29.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 67 | 188 | $63,168 | $15,556 | 24.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 49 | 50 | $32,700 | $7,883 | 24.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 31 | 32 | $11,008 | $3,381 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 28 | 37 | $8,584 | $2,399 | 27.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 13 | 16 | $7,424 | $1,657 | 22.3% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2021 | 13 | 13 | $3,588 | $705.84 | 19.7% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 22 | 189 | $185,976 | $43,917 | 23.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 82 | 185 | $62,160 | $15,969 | 25.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 60 | 62 | $40,548 | $10,349 | 25.5% |
| 90935 | Hemodialysis procedure with one physician evaluation | Facility | 2020 | 64 | 112 | $30,912 | $6,531 | 21.1% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 29 | 29 | $10,063 | $2,170 | 21.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 31 | 36 | $8,352 | $2,143 | 25.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 16 | 16 | $7,424 | $1,294 | 17.4% |
About Dr. Biff Palmer, MD
Dr. Biff Palmer, MD is a Internal Medicine healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053380550.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Biff Palmer, MD has received a total of $980,569 in payments from pharmaceutical and medical device companies, with $54,050 received in 2024. These payments were reported across 1,076 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($677,034).
As a Medicare-enrolled provider, Palmer has provided services to 936 Medicare beneficiaries, totaling 1,921 services with total Medicare billing of $256,355. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Dallas, TX
- Active Since 03/16/2006
- Last Updated 04/16/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1053380550
Products in Payments
- Kerendia (Drug) $285,451
- LOKELMA (Drug) $259,070
- FARXIGA (Drug) $134,050
- Veltassa (Drug) $94,642
- SAMSCA (Drug) $52,190
- ACTHAR (Biological) $31,259
- JARDIANCE (Drug) $26,177
- KRYSTEXXA (Drug) $8,132
- Vaprisol Dextrose in Plastic Container (Drug) $7,000
- Non-Covered $6,638
- INVOKANA (Drug) $5,739
- Vaprisol (Drug) $5,220
- TOLVAPTAN (Drug) $4,427
- TARPEYO (Drug) $2,074
- VIBATIV (Drug) $2,000
- NO PRODUCT DISCUSSED (Drug) $1,152
- EPOGEN (Biological) $100.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Dallas
Andrew Whiteley
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. Robert Gottlieb, M.d. Ph.d, M.D. PH.D
Internal Medicine — Payments: $832,284
Internal Medicine $832,284
Dr. Ronan Kelly, Md, MD
Internal Medicine — Payments: $813,092
Internal Medicine $813,092
Dr. Gates Colbert, M.d, M.D
Internal Medicine — Payments: $801,349
Internal Medicine $801,349
Dr. Zoran Kurepa, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $743,379
Internal Medicine $743,379
Dr. Edward Pearson, Md, MD
Internal Medicine — Payments: $728,183
Internal Medicine $728,183